[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Alabama at Birmingham\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":575},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,280,0,25,[9,44,67,92,114,137,159,179,217,239,261,280,300,316,348,368,394,416,434,460,478,496,516,533,551],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100603356","phase-4-induction-of-cross-protective-antibodies-for-serogroup-33-by-pneumococcal-conjugate-vaccines-100603356",false,"NCT07135453","Induction of Cross-protective Antibodies for Serogroup 33 by Pneumococcal Conjugate Vaccines","Novel Serotype Alert: Investigate New Pneumococcal Conjugate Vaccines for Inducing Cross-protection Against Newly Discovered Serotype 33E and Putative Novel Serogroup 33 Serotypes","Group 33\u002FPCVs","Inclusion Criteria:\n\n* Healthy adult\n\nExclusion Criteria:\n\n* No prior history of pneumococcal vaccination\n* No immunosuppressing medications or chronic diseases that affect immune function",true,"ALL","18 Years",{"count":22,"type":23},70,"ESTIMATED","INTERVENTIONAL",[26],"PHASE4","The goal of this study is to learn whether different types of vaccines to prevent bacterial infections are able to effectively create antibodies that defend against certain types of bacteria.\n\nWe will give two different types of vaccine and evaluate the effectiveness of antibodies produced by each vaccine in killing bacteria.",[29,30],"Vaccine","Pneumococcal Disease","RECRUITING","2026-08-20",{"date":34,"type":35},"2026-08-21","ACTUAL",{"date":37,"type":35},"2026-07-01",{"date":39,"type":23},"2027-08",{"name":41,"class":42},"University of Alabama at Birmingham","OTHER",1,{"id":45,"slug":46,"hasResults":12,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":24,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":43},"100652604","improving-delivery-of-aging-related-supportive-care-for-older-adults-with-acute-myeloid-leukemia-100652604","NCT07777471","Improving Delivery of Aging-Related Supportive Care for Older Adults With Acute Myeloid Leukemia","Active Default Pilot: Implementation of Geriatric Assessment-Driven Supportive Care for Older Adults With Acute Myeloid Leukemia Receiving Venetoclax-Based Therapy","ACTIVE DEFAULT","Inclusion Criteria:\n\nPatient participants:\n\n* Age 60 years or older\n* Newly diagnosed acute myeloid leukemia (AML), including de novo, secondary, or therapy-related AML, per current World Health Organization (WHO) or International Consensus Classification (ICC) classification\n* Planned for first-line venetoclax-based lower-intensity therapy\n* English-speaking\n* Able to provide informed consent personally or through a Legally Authorized Representative (LAR)\n\nProvider participants:\n\n-Participating leukemia attending physicians and supportive care service leads involved in the care of enrolled participants\n\nExclusion Criteria:\n\nPatient participants:\n\n* Acute promyelocytic leukemia\n* Planned intensive induction or non-venetoclax-based therapy\n* Life expectancy under 14 days or hospice enrollment at screening",{"count":53,"type":23},40,[55],"NA","The goal of this clinical trial is to test a way of delivering supportive care to adults 60 years and older who are starting venetoclax-based treatment for newly diagnosed acute myeloid leukemia (AML). Older adults with AML often have aging-related needs, such as problems with mobility, nutrition, mood, memory, or medications, that are not always addressed in a consistent way. In this study, a health questionnaire and short in-person checks (a geriatric assessment) are used to find these needs early, and matching supportive care orders are prepared in the electronic health record and sent to the treating doctor, who decides whether to place each one. This approach is called Active Default. The main questions the study aims to answer are:\n\n* How often are the prepared supportive care orders signed by treating doctors (implementation fidelity)?\n* Can each step of the process, from completing the assessment to receiving supportive care services, be carried out as planned?\n\nParticipants will:\n\n* Complete questionnaires and short in-person checks of walking, balance, strength, memory, mood, and medications at the start of treatment\n* Receive supportive care services (for example physical therapy, nutrition, or social work) if their doctor approves the prepared orders\n* Answer phone check-ins over 90 days and repeat two short checks at about two months\n* Be invited to one optional interview about their experience\n\nHealthcare providers involved in participants' care will be invited to complete a one-time survey and an optional interview about the approach.",[58],"Acute Myeloid Leukemia (AML)","NOT_YET_RECRUITING","2026-08-19",{"date":34,"type":35},{"date":63,"type":23},"2026-10-01",{"date":65,"type":23},"2028-09-30",{"name":41,"class":42},{"id":68,"slug":69,"hasResults":12,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":24,"phases":77,"briefSummary":79,"conditions":80,"keywords":83,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":86,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":43},"100645370","phase-2-daily-encapsulated-green-tea-extract-to-mitigate-neuropathic-pain-in-patients-with-established-cancer-associated-neuropathic-pain-100645370","NCT07682324","Daily, Encapsulated, Green Tea Extract to Mitigate Neuropathic Pain in Patients With Established Cancer-Associated Neuropathic Pain","Daily, Encapsulated, Green Tea Extract (GTE) to Mitigate Neuropathic Pain in Patients With Established Cancer-Associated Neuropathic Pain","GTE","Inclusion Criteria:\n\n* 18 years of age or older.\n* Established cancer-associated neuropathic pain.\n* A baseline Douler Neuropathique 4 (DN4) patient-reported neuropathic pain questionnaire score of greater than or equal to 4.\n* A stable pain management medication regimen, with no more than a 10% change in dosage in the past 14 days prior to enrollment.\n* No known allergy to rice or rice flour (basis of placebo).\n\nExclusion Criteria:\n\n* Actively undergoing cancer treatment.\n* Symptoms and\u002For diagnosis of diabetic peripheral neuropathy.\n* Self-describe as consuming more than 3 cups of green tea or matcha beverages on a daily basis.\n* High probability of completing the study and all study-related measures\u002Factivities required by the protocol.",{"count":76,"type":23},20,[78],"PHASE1","The overall objective of this study is to test an intervention of green tea extract (GTE) to mitigate neuropathic pain in patients, specifically cancer survivors, receiving supportive palliative care. The central hypothesis is that daily, oral, encapsulated GTE will mitigate neuropathic pain, as longitudinally measured by the validated Douleur Neuropathique 4 (DN4) and blood protein biomarkers reported to be linked to the development and\u002For chronicity of neuropathic pain.",[81,82],"Neuropathic Pain","Cancer Treatment",[84,73,85],"green tea extract","neuropathic pain",{"date":34,"type":35},{"date":88,"type":23},"2026-09-30",{"date":90,"type":23},"2029-03-01",{"name":41,"class":42},{"id":93,"slug":94,"hasResults":12,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":18,"sex":19,"minAge":99,"maxAge":4,"enrollmentInfo":100,"targetDuration":4,"studyType":101,"phases":4,"briefSummary":102,"conditions":103,"keywords":105,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":108,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":43},"100640425","development-of-healthcare-transition-for-patients-with-congenital-adrenal-hyperplasia-100640425","NCT07611786","Development of Healthcare Transition for Patients With Congenital Adrenal Hyperplasia","Evaluation of a Healthcare Transition Protocol for Patients With Congenital Adrenal Hyperplasia","Inclusion Criteria:\n\nYA Participants\n\n* Diagnosis of congenital adrenal hyperplasia (any subtype or severity)\n* Age ≥16 years\n* Active follow-up within the pediatric endocrinology clinic\n* English-speaking\n* Cognitively able to complete questionnaires with or without assistance\n* Anticipated ability to participate in CAH-T visits during the study period Caregiver Participants\n* Parent, guardian, or primary support person of an enrolled AYA participant Provider Participants\n* Pediatric endocrinologists, nurse practitioners, or transition-related clinical staff involved in CAH care for at least 6 months\n\nExclusion Criteria:\n\n* Significant cognitive impairment precluding participation\n* Inability to complete study procedures\n* Inability to provide informed consent\u002Fassent","16 Years",{"count":53,"type":23},"OBSERVATIONAL","The purpose of this study is to implement and evaluate the feasibility and acceptability of a structured healthcare transition program for adolescents and young adults with congenital adrenal hyperplasia (CAH). The study will also examine preliminary effects of the program on transition readiness, disease-specific self-management knowledge, emergency preparedness, continuity of endocrine care, and health-related quality of life as participants transition from pediatric to adult healthcare services.",[104],"Congenital Adrenal Hyperplasia",[106,107],"congenital adrenal hyperplasia","healthcare transition",{"date":34,"type":35},{"date":110,"type":23},"2026-10",{"date":112,"type":23},"2029-10",{"name":41,"class":42},{"id":115,"slug":116,"hasResults":12,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":12,"sex":19,"minAge":121,"maxAge":20,"enrollmentInfo":122,"targetDuration":4,"studyType":24,"phases":123,"briefSummary":124,"conditions":125,"keywords":127,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":131,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":4},"100633767","omega-3-fatty-acids-in-children-with-sickle-cell-disease-100633767","NCT07530965","Omega-3-Fatty Acids in Children With Sickle Cell Disease","A Single Arm\u002F Open Label Feasibility Trial of Omega-3- Fatty Acids in Children With Sickle Cell Disease","Inclusion Criteria:\n\n\\- Children 5-18 years with SCD at steady state. Steady state will be defined as not requiring an acute care visit for pain in the last 28 days.\n\nExclusion Criteria:\n\n* current use of antibiotics except prophylactic penicillin\n* current use of pre-or probiotic supplements\n* current use of PPI therapy\n* pregnant or lactating females\n* individuals with known allergy to Flaxseed","5 Years",{"count":76,"type":23},[55],"The purpose of this feasibility study is to investigate the role of a dietary supplement in modulating the gut microbiota and improving pain outcomes in children with sickle cell disease (SCD).",[126],"Sickle Cell Disease (SCD)",[128,129,130],"Nutritional trial","sickle cell disease","children",{"date":34,"type":35},{"date":133,"type":23},"2026-12-01",{"date":135,"type":23},"2029-06-30",{"name":41,"class":42},{"id":138,"slug":139,"hasResults":12,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":4,"eligibilityCriteria":143,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":144,"enrollmentInfo":145,"targetDuration":4,"studyType":24,"phases":147,"briefSummary":149,"conditions":150,"keywords":152,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":154,"startDateStruct":155,"completionDateStruct":156,"leadSponsor":158,"locationsCount":43},"100614890","phase-2-low-dose-naltrexone-for-mecfs-dose-finding-100614890","NCT07285473","Low-Dose Naltrexone For ME\u002FCFS: Dose-Finding","Low-dose Naltrexone (LDN) for the Treatment of Myalgic Encephalomyelitis\u002FChronic Fatigue Syndrome (ME\u002FCFS): Dose-Finding","Inclusion Criteria:\n\n* Between ages of 18 and 65\n* Living in Alabama\n* Meets ME-ICC criteria\n\nExclusion Criteria:\n\n* Abnormal hepatic function\n* Abnormal renal function\n* Abnormal complete blood count\n* Evidence of active or chronic systemic infection\n* A1C \\> 9.0%\n* Current opioid analgesic use\n* Pregnant or plans to become pregnant during the study participation period\n* Auto-immune disorder\n* Enrolled in other experimental treatment study","65 Years",{"count":146,"type":23},75,[148],"PHASE2","This exploratory clinical trial tests low-dose naltrexone (LDN) for the treatment of Myalgic Encephalomyelitis\u002FChronic Fatigue Syndrome (ME\u002FCFS). A remote trial approach is used, with eligibility open to the state of Alabama.",[151],"Myalgic Encephalomyelitis\u002FChronic Fatigue Syndrome",[151,153],"ME\u002FCFS",{"date":34,"type":35},{"date":63,"type":23},{"date":157,"type":23},"2028-04-01",{"name":41,"class":42},{"id":160,"slug":161,"hasResults":12,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":166,"targetDuration":4,"studyType":24,"phases":167,"briefSummary":169,"conditions":170,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":43},"100652912","early-phase-1-multiparametric-metabolic-and-hypoxic-petmri-imaging-substudy-in-gliomas-100652912","NCT07778979","Multiparametric Metabolic and Hypoxic PET\u002FMRI Imaging Substudy in Gliomas","Multiparametric Metabolic and Hypoxic PET\u002FMRI Imaging Substudy for Disease Assessment and Guidance of Catheters in Patients With Recurrent\u002FProgressive Malignant Gliomas Eligible for Catheter-delivered Therapies","Inclusion Criteria:\n\n1. Participants from IRB 300007756\n2. 18 years of age or older at the time of enrollment\n3. Able to undergo PET\u002FMRI without anesthesia or sedation. Minimal sedation with ananxiolytic such as alprazolam used routinely for SOC MRI is allowed.\n4. Females with childbearing potential must have a negative urine β-hCG test on the day of procedure or a serum hCG test within 48 hours prior to the administration of FET or FMISO.\n5. ECOG performance score of 2 or better\n6. Life expectancy greater than 12 weeks.\n\nExclusion Criteria:\n\n1. Any exclusions listed in IRB 300007756\n2. Pregnancy or breast feeding\n3. Inability to complete PET\u002FMRI scans.\n4. Significant renal dysfunction (estimated GFR \\\u003C 30 mL\u002Fmin)\n5. Any condition which may interfere with ability to participate in or complete all study-related activities as assessed by the study team\n6. Unable to undergo MRI\n7. Contraindication to gadolinium-based contrast",{"count":76,"type":23},[168],"EARLY_PHASE1","This substudy will investigate a new imaging approach using positron emission tomography (PET) and two investigational drugs (\\[18F\\]FET and \\[18F\\]FMISO) to see if the imaging results will help with the placement of catheters for therapy delivery in 20 adult patients with malignant gliomas (MGs) who are participating in the UAB IRB approved main study, A Phase I\u002FII Study of Pembrolizumab and M032 (NSC 733972), a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent\u002FProgressive and Newly Diagnosed Glioblastoma Multiforme, grade 3 or grade 4 astrocytoma, or Gliosarcoma (IRB 300007756 PI Markert). The PET and MR imaging results will be available to guide catheter placement within IRB 300007756 study-specific guidelines during Neurosurgery.",[171],"Glioma","2026-08-18",{"date":34,"type":35},{"date":175,"type":23},"2026-09",{"date":177,"type":23},"2030-11",{"name":41,"class":42},{"id":180,"slug":181,"hasResults":12,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":185,"eligibilityCriteria":186,"healthyVolunteers":12,"sex":187,"minAge":99,"maxAge":188,"enrollmentInfo":189,"targetDuration":4,"studyType":24,"phases":191,"briefSummary":192,"conditions":193,"keywords":201,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":211,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":43},"100652879","community-health-worker-support-to-lower-blood-pressure-after-a-pregnancy-with-high-blood-pressure-100652879","NCT07778966","Community Health Worker Support to Lower Blood Pressure After a Pregnancy With High Blood Pressure","Alabama Womb to Heart Solution: A Community-Based Cardiovascular Health Intervention After Hypertension in Pregnancy","AW2H","Inclusion Criteria:\n\n* Postpartum patients with pregnancy-associated hypertension (gestational hypertension, preeclampsia, eclampsia, hypertension with superimposed preeclampsia, or HELLP syndrome) or stage 2 hypertension per ACC\u002FAHA guidelines (SBP \\>=140 mmHg or DBP \\>=90 mmHg) on two separate occasions at delivery-related hospital discharge or during the postpartum period\n* Delivered in the last six weeks at \\>=14 weeks gestational age, including pregnancy loss\n* 16-56 years old\n* Speaks and writes in English\n* Delivering at UAB Hospital\n\nExclusion Criteria:\n\n* Declines randomization\n* Does not speak English\n* Currently incarcerated\n* Currently enrolled in other community health worker studies or services","FEMALE","56 Years",{"count":190,"type":23},174,[55],"High blood pressure during or after pregnancy (such as preeclampsia, gestational hypertension, eclampsia, or HELLP syndrome) raises a mother's risk of heart disease later in life. Many patients do not return for follow-up care after delivery, missing a key window to protect their heart health. The Alabama Womb to Heart Solution (AW2H) trial will test whether pairing postpartum patients with a trained community health worker (CHW) for 6 months lowers blood pressure compared with usual care.\n\nA total of 174 postpartum patients who had pregnancy-associated hypertension or stage 2 high blood pressure will be randomly assigned (1:1) to usual care or usual care plus the AW2H CHW program. All participants receive education on measuring their own blood pressure and a pregnancy-validated home blood pressure monitor. Participants in the CHW group are also contacted regularly by a CHW for 6 months. CHWs coach home blood pressure monitoring, support taking blood pressure medications as prescribed, encourage heart-healthy habits based on the American Heart Association's Life's Essential 8, help schedule a primary care visit, provide mother-baby education (such as safe sleep and immunizations), and offer emotional support.\n\nThe main outcome is systolic blood pressure 6 months after enrollment, measured at home with the study-provided monitor while a research coordinator observes in person or by video\u002Fphone. The study will also look at diastolic blood pressure and whether participants scheduled a primary care visit. Interviews and focus groups will explore participant, CHW, and provider experiences with the program.",[194,195,196,197,198,199,200],"Pregnancy-Associated Hypertension","Gestational Hypertension","Preeclampsia","Eclampsia","HELLP Syndrome","Hypertension, Stage 2","Postpartum Hypertension",[202,203,204,205,206,207,208,209,210],"Community health worker","Postpartum","Blood pressure","Self-measured blood pressure monitoring","Cardiovascular disease prevention","Life's Essential 8","Hypertensive disorders of pregnancy","Alabama","Primary care linkage",{"date":34,"type":35},{"date":213,"type":23},"2026-08-31",{"date":215,"type":23},"2030-07-30",{"name":41,"class":42},{"id":218,"slug":219,"hasResults":12,"nctId":220,"briefTitle":221,"officialTitle":222,"acronym":4,"eligibilityCriteria":223,"healthyVolunteers":12,"sex":19,"minAge":99,"maxAge":224,"enrollmentInfo":225,"targetDuration":4,"studyType":24,"phases":226,"briefSummary":227,"conditions":228,"keywords":230,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":235,"completionDateStruct":236,"leadSponsor":238,"locationsCount":43},"100652657","the-effect-of-lateral-extra-articular-tenodesis-on-lower-extremity-lean-mass-recovery-following-anterior-cruciate-ligament-reconstruction-100652657","NCT07777458","The Effect of Lateral Extra-Articular Tenodesis on Lower-Extremity Lean Mass Recovery Following Anterior Cruciate Ligament Reconstruction","The Effect of Lateral Extra-Articular Tenodesis on Lower-Extremity Lean Mass Recovery Following Anterior Cruciate Ligament Reconstruction: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Skeletally mature patients less than or equal to 60 years of age with ACL insufficiency scheduled to undergo primary BTB ACL reconstruction with or without LET.\n* Patients presenting with acute ACL injuries. Patients presenting with acute ACL injuries will be eligible for enrollment.\n* Acute injuries will be defined as injuries occurring within 6 weeks of presentation.\n\nExclusion Criteria:\n\n* undergoing multi ligamentous reconstruction (PCL, MCL, or PLC)\n* revision ACL reconstruction\n* neuromuscular disorders\n* contralateral ACL injury\n* pregnant or nursing\n* unable to read or write in English\n* possessing a high likelihood of remaining non-compliant\n* desire to return to sport prior to 6 months.","60 Years",{"count":53,"type":23},[55],"The purpose of this study is to determine whether the addition of Lateral Extra-Articular Tenodesis (LET) influences postoperative lower-extremity LM recovery following bone-patellar tendon-bone (BTB) Anterior Cruciate Ligament Reconstruction (ACLR). We hypothesize that patients undergoing ACLR BTB with LET will demonstrate greater loss of operative-leg LM at 9 months postoperatively compared with patients undergoing isolated ACLR BTB.",[229],"Anterior Cruciate Ligament Reconstruction (ACLR)",[231,232,229],"Lateral Extra-Articular Tenodesis (LET)","Bone-Patellar Tendon-Bone (BTB)","2026-08-17",{"date":32,"type":35},{"date":110,"type":23},{"date":237,"type":23},"2031-08",{"name":41,"class":42},{"id":240,"slug":241,"hasResults":12,"nctId":242,"briefTitle":243,"officialTitle":243,"acronym":4,"eligibilityCriteria":244,"healthyVolunteers":18,"sex":19,"minAge":245,"maxAge":246,"enrollmentInfo":247,"targetDuration":4,"studyType":24,"phases":249,"briefSummary":250,"conditions":251,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":255,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":43},"100491235","early-phase-1-mefamp-for-imaging-system-a-amino-acid-transport-in-primary-and-metastatic-brain-tumors-100491235","NCT05676489","MeFAMP for Imaging System A Amino Acid Transport in Primary and Metastatic Brain Tumors","Inclusion Criteria for all cohorts:\n\n1. 18 years of age or older at the time of enrollment\n2. Females with childbearing potential must have a negative urine human chorionic gonadotropin (hCG) test on the day of procedure or a serum hCG test within 48 hours prior to the administration MeFAMP.\n3. Must have a life expectancy greater than 12 weeks.\n\nExclusion Criteria for all cohorts:\n\n1. Use of an investigational drug for any indication within 3 months prior to the imaging study.\n2. Pregnancy or breast feeding\n3. Inability to complete the PET scans.\n4. Significant renal or hepatic dysfunction (estimated glomerular filtration rate (GFR) \\\u003C 60 mL\u002Fmin)\n5. Any condition which may interfere with ability to participate in or complete all study-related activities as assessed by the study team.\n\n6.4.9.3. Inclusion criteria specific to Dosimetry Cohort\n\n1. Normal complete metabolic profile (CMP) and cell blood count (CBC) with differential at baseline.\n2. Normal ECG at baseline.\n\nExclusion criteria specific to Dosimetry Cohort\n\n1\\) Major medical problems (e.g. renal, hepatic, inflammatory) that could interfere with biodistribution of MeFAMP as assessed by the study team.\n\nInclusion Criteria specific to HGG Cohort\n\n1. Grade III or Grade IV glioma previously treated with radiation therapy\n2. Standard of care contrast-enhanced MRI showing an enhancing lesion at least 1-cm in maximum dimension that is equivocal or suspicious for recurrent glioma.\n3. Eastern Cooperative Oncology Group (ECOG) performance score of 2 or better\n\nInclusion Criteria specific to Metastasis Cohort\n\n1. At least one brain metastasis from melanoma, lung cancer (small or non-small cell), or breast cancer measuring at least 1-cm in maximum dimension on contrast-enhanced MRI\n2. Plan for stereotactic radiation therapy within 2 weeks of initial MeFAMP-PET\u002FMRI scan.\n3. ECOG performance score of 2 or better\n\nInclusion of Women and Minorities\n\nPatients 18 years of age or older will be eligible for study participation. No other discriminatory factors, including age, sex, or ethnic background will be used to determine eligibility. Every effort will be made to ensure that minorities are recruited for study participation.","18 Months","89 Years",{"count":248,"type":23},28,[168],"This first-in-human study will establish the human safety and radiation dosimetry of the system A amino acid transport substrate, (R)-3-\\[F-18\\]fluoro-2-methyl-2-(methylamino)propanoic acid (\\[F-18\\]MeFAMP), for positron emission tomography (PET) imaging of primary and metastatic brain tumors. This study will include 3 cohorts: healthy volunteers for whole body dosimetry estimates (n=6-8, Dosimetry Cohort), patients undergoing evaluation for recurrent high grade glioma after radiation therapy (n=10, high grade glioma (HGG) Cohort), and patients with brain metastases from extra-cranial solid tumors before and after radiation therapy (n=10, Metastasis Cohort). Exploratory assessment of the diagnostic accuracy of MeFAMP for distinguishing recurrent\u002Fprogressive brain tumors from radiation-related treatment effects will also be performed for subsequent trial design. The study will complete accrual and safety assessment in the Dosimetry Cohort before recruiting for the HGG and Metastasis Cohorts.",[252,253,254],"Healthy Volunteers","Recurrent Glioma","Brain Metastases From Extra-cranial Solid Tumors",{"date":32,"type":35},{"date":257,"type":23},"2027-04-01",{"date":259,"type":23},"2029-08-30",{"name":41,"class":42},{"id":262,"slug":263,"hasResults":12,"nctId":264,"briefTitle":265,"officialTitle":265,"acronym":4,"eligibilityCriteria":266,"healthyVolunteers":12,"sex":19,"minAge":267,"maxAge":246,"enrollmentInfo":268,"targetDuration":4,"studyType":24,"phases":269,"briefSummary":270,"conditions":271,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":273,"startDateStruct":274,"completionDateStruct":276,"leadSponsor":278,"locationsCount":279},"100487858","early-phase-1-multiparametic-metabolic-and-hypoxic-petmri-for-disease-assessment-in-high-grade-glioma-100487858","NCT05632562","Multiparametic Metabolic and Hypoxic PET\u002FMRI for Disease Assessment in High Grade Glioma","Inclusion Criteria:\n\n1. Histologically confirmed newly diagnosed grade III or grade IV glioma treated with standard of care external beam radiation therapy (RT). For diffuse midline glioma involving the pons (diffuse intrinsic pontine glioma), histological confirmation is not required. Surgical resection of the glioma prior to RT and\u002For concurrent temozolomide (TMZ) with RT are allowed but not required.\n2. 10 years of age or older at the time of enrollment\n3. Able to undergo PET\u002FMRI without anesthesia or sedation. Minimal sedation with an anxiolytic such as alprazolam used routinely for SOC MRI is allowed.\n4. Females with childbearing potential must have a negative urine β-hCG test on the day of procedure or a serum beta-hCG test within 48 hours prior to the administration of FET or FMISO.\n5. ECOG performance score of 2 or better in adults. For patients less than 16 years of age, Modified Lansky score ≥ 60.\n6. Life expectancy greater than 12 weeks.\n\nExclusion Criteria:\n\n1. Recurrent glioma\n2. Use of bevacizumab or an investigational therapeutic drug for any indication within 3 months prior to the imaging study.\n3. Pregnancy or breast feeding\n4. Inability to complete PET\u002FMRI scans.\n5. Significant renal dysfunction (estimated GFR \\\u003C 30 mL\u002Fmin)\n6. Any condition which may interfere with ability to participate in or complete all study-related activities as assessed by the study team\n7. Time interval greater than 12 weeks between the completion of RT and performance of FET and FMISO PET\u002FMRI studies.","10 Years",{"count":76,"type":23},[168],"This feasibility study will assess the clinical potential of a new imaging approach to detect viable high grade glioma (HGG) in pediatric and adult patients after standard of care radiation therapy (RT) with or without concurrent temozolomide (TMZ). Study participants will undergo simultaneous positron emission tomography\u002Fmagnetic resonance imaging (PET\u002FMRI) with O-(\\[2-\\[F-18\\]fluoroethyl)-L-tyrosine (FET, amino acid transport) and 1H-1-(3-\\[F-18\\]fluoro-2-hydroxypropyl)-2-nitroimidazole (FMISO, hypoxia) at the time of standard of care imaging after completion of RT. The presence of viable tumor at this time point will be assessed on a per patient basis. Study participants will be followed clinically and with standard of care (SOC) imaging for up to 2 years after completion of PET\u002FMRI to determine the nature of lesions seen on investigational imaging and to obtain patient outcome data. The imaging data will also be used to develop a semi-automated workflow suitable for implementation in clinical trials and standard of care PET\u002FMRI studies.",[272],"High Grade Glioma",{"date":32,"type":35},{"date":275,"type":35},"2024-03-07",{"date":277,"type":23},"2028-02-01",{"name":41,"class":42},2,{"id":281,"slug":282,"hasResults":12,"nctId":283,"briefTitle":284,"officialTitle":285,"acronym":4,"eligibilityCriteria":286,"healthyVolunteers":12,"sex":187,"minAge":20,"maxAge":287,"enrollmentInfo":288,"targetDuration":4,"studyType":24,"phases":289,"briefSummary":290,"conditions":291,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":293,"lastUpdatePostDateStruct":294,"startDateStruct":295,"completionDateStruct":297,"leadSponsor":299,"locationsCount":43},"100428593","early-phase-1-monitoring-breast-cancer-immunotherapy-treatment-with-advanced-positron-emission-tomography-magnetic-resonance-imaging-petmri-100428593","NCT04861077","Monitoring Breast Cancer Immunotherapy Treatment With Advanced Positron Emission Tomography Magnetic Resonance Imaging (PET\u002FMRI)","Monitoring Breast Cancer Immunotherapy Treatment With Advanced PET\u002FMRI: A Pilot Study","Inclusion Criteria:\n\n1. Patients must be ≥ 18 years old and ≤ 75 years old\n2. Triple negative breast cancer (TNBC) patients (biopsy-proven) stage II-IV eligible\n3. \\>50%Programmed death-ligand 1 (PD-L1) positive\n4. Eligible for immunotherapy who are naïve to beginning any immunotherapy treatment\n5. May not be pregnant or breastfeeding\n6. Subjects must be willing to sign consent\n7. Adequate creatinine clearance per institutional guidelines and within 30 days\n8. Estimated life expectancy of greater than one year\n9. Patients must have one lesion with RECIST measurable disease (greater than 1 cm in diameter, measured from diagnostic breast MRI or staging CT)\n\nExclusion Criteria:\n\n1. Inability to provide informed consent\n2. Weight over 350 lbs., due to the scanner bore size\n3. Lactating, known or suspected pregnancy. Women with child-bearing potential must a have a negative serum Human chorionic gonadotropin (β-hCG) pregnancy test within 48 hours or a negative urine β-hCG pregnancy test within 24 hours of each PET imaging study.\n4. Contraindication for MRI study (e.g. non-removable metal implants or certain tattoos)\n5. Unable to lie still on the imaging table for one (1) hour\n6. contraindication for gadolinium-based contrast agent, ProHance (gadoteridol)\n7. Have received immunotherapy in the neoadjuvant or adjuvant setting","75 Years",{"count":76,"type":23},[168],"This clinical study will investigate the utility of Fludeoxyglucose (18F) fluoromisonidazole (FMISO), in patients diagnosed with triple negative breast cancer (stage II-IV disease), to monitor and predict the effect of immunotherapy. This is a parallel imaging study to current treatment strategies and no clinical decisions or outcomes will be based on the imaging. If promising, this data will be used to design larger trials. A total of 20 patients will be recruited for this study. This trial will not designate the participant's treatment plan; they will be eligible based on their treatment plan designated from their oncologist.",[292],"Triple Negative Breast Cancer","2026-08-13",{"date":233,"type":35},{"date":296,"type":23},"2027-06",{"date":298,"type":23},"2030-08",{"name":41,"class":42},{"id":301,"slug":302,"hasResults":12,"nctId":303,"briefTitle":304,"officialTitle":304,"acronym":4,"eligibilityCriteria":305,"healthyVolunteers":12,"sex":187,"minAge":20,"maxAge":4,"enrollmentInfo":306,"targetDuration":4,"studyType":24,"phases":307,"briefSummary":308,"conditions":309,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":293,"lastUpdatePostDateStruct":311,"startDateStruct":312,"completionDateStruct":314,"leadSponsor":315,"locationsCount":43},"100388039","phase-1-monitoring-her2-breast-cancer-neoadjuvant-treatment-with-advanced-petmri-100388039","NCT04332588","Monitoring HER2+ Breast Cancer Neoadjuvant Treatment With Advanced PET\u002FMRI","Inclusion Criteria:\n\n1. Patients must be ≥ 18 years old and ≤ 75 years old\n2. HER2+ breast cancer determined on primary tumor by a local pathology laboratory and defined as IHC score 3+ and\u002For positive by ISH (defined by ISH ratio of ≥ 2.0 for the number of HER2 gene copies to the number of chromosome 17 copies). Only one positive result is required for eligibility\n3. Locally advanced stage II-III HER2+ breast cancer patients eligible for neoadjuvant therapy who are naïve to beginning treatment\n4. Estimated life expectancy of greater than one year\n5. Patients must have one lesion with RECIST measurable disease (great than 1 cm in diameter)\n\nExclusion Criteria:\n\n1. Inability to provide informed consent F\n2. Weight over 350 lbs., due to the scanner bore size\n3. Lactating, known or suspected pregnancy. Women with child-bearing potential must a have a negative serum β-hCG pregnancy test within 48 hours or a negative urine β-hCG pregnancy test within 48 hours of each PET imaging study.\n4. Contraindication for MRI study (e.g. non-removable metal implants or certain tattoos)\n5. Unable to lie still on the imaging table for one (1) hour\n6. contraindication for gadolinium-based contrast agent, ProHance (gadoteridol)",{"count":7,"type":23},[78],"The purpose of the study is to see if using an investigational drug called \\[18F\\]FMISO with PET\u002FMRI imaging can help monitor and predict the effect of trastuzumab (Herceptin) on chemotherapy in patients diagnosed with advanced HER2 positive breast cancer. This study is for imaging purposes only and is not a treatment study. The results of this study will not change a patient's clinical treatment plan but it may help physicians and researchers better understand how best to treat patients with breast cancer in the future.",[310],"HER2-positive Breast Cancer",{"date":233,"type":35},{"date":313,"type":35},"2022-03-25",{"date":39,"type":23},{"name":41,"class":42},{"id":317,"slug":318,"hasResults":12,"nctId":319,"briefTitle":320,"officialTitle":321,"acronym":4,"eligibilityCriteria":322,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":323,"targetDuration":4,"studyType":24,"phases":325,"briefSummary":326,"conditions":327,"keywords":335,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":340,"lastUpdatePostDateStruct":341,"startDateStruct":343,"completionDateStruct":345,"leadSponsor":347,"locationsCount":43},"100633163","mecfs-brain-fog-cognitive-rehabilitation-trial-100633163","NCT07523113","ME\u002FCFS Brain Fog: Cognitive Rehabilitation Trial","Brain Training for Chronic, Post-viral, Brain Fog: Study A","Inclusion Criteria:\n\n* diagnosis of ME\u002FCFS that preceded cognitive complaints\n* mild or greater cognitive impairment\n* moderate or greater brain fog\n* some impairment in the performance of daily activities\n* ≥ 18 years, no upper limit if medically stable\n* reside in the community (as opposed to a hospital or skilled nursing facility)\n* able to travel to the laboratory on multiple occasions\n* has Internet service\n* has a personal computer, laptop, or tablet that can access the Internet\n* sufficiently fit, from both a physical and mental health perspective, to take part in the study\n* adequate sight and hearing to complete the UFOV test\n* adequate thinking skills, e.g., ability to follow directions and retain information to complete UFOV and CTAL, as marked by the judgement of the screener that the candidate is able to adequately complete the UFOV and CTAL\n* sufficient English proficiency (i.e., ability to speak, understand, read, and write to take part in study activities)\n\nExclusion Criteria:\n\n* cognitive impairment due to a developmental disability, psychiatric disorder, or substance abuse, or due to another type of brain injury, such as traumatic brain injury, stroke, or a progressive brain disease, such as Alzheimer's Dementia\n* current substance abuse disorder\n* diagnosis of postural orthostatic tachycardia syndrome (POTS) by a healthcare provider\n* prior cognitive processing speed training on DoubleDecision or a similar program\n* cannot tolerate taVNS\n* prior history of heart attack or other serious cardiac events\n* implanted medical device of any type\n* vasovagal syncope or history of fainting\n* history of seizures or epilepsy\n* temporomandibular Joint (TMJ) syndrome or other conditions that cause substantial jaw pain\n* history of peripheral nerve injury to the head, neck, or face\n* pregnant or breastfeeding\n* not able or willing to get an MRI scan\n* not able or willing to get a blood draw",{"count":324,"type":23},30,[55],"The purpose of this study is to compare two approaches to cognitive rehabilitation in adults with post-viral cognitive syndrome, which resulted in brain fog. All participants will be screened for eligibility prior to participation. Most of the procedures will take place over a phone call or secure telehealth platform (i.e., Zoom). However, participants will be asked to visit UAB on three occasions for blood sample collection and brain imaging (about 2 hours each). Online testing will happen one month before treatment, one day before treatment, one day afterwards, and 6 months afterwards. The study will utilize two different forms of rehabilitation training to improve participants' cognitive ability. Participants will be randomized to one of the two treatment groups. The first treatment approach, known as Constraint-Induced Cognitive Therapy (CICT), will feature (A) web-based computer \"games\" that trains how quickly individuals process information that they receive through their senses; (B) online training on everyday activities with important cognitive components, (C) procedures designed to transfer improvements in cognition from the treatment setting to everyday life, and (D) a non-invasive form of vagus nerve stimulation, also known as trans-auricular VNS (taVNS). The second approach, known as Brain Fitness Training (BFT), will include (A) web-based computer \"games\" that train reaction time and eye-hand coordination; (B) in-lab training on relaxation, breathing, healthy nutrition, and healthy sleep, (C) education about how relaxation, breathing, nutrition, and sleep are connected to thinking effectiveness, and (D) taVNS. Approximately 30 hours of training will be conducted over a secure telehealth platform (i.e., Zoom) in the span of two- to four- weeks. A typical CICT session will consist of one hour of gaming, with the bulk of the session being spent on cognitive training of the target behaviors and procedures designed to promote transfer of therapeutic gains to daily life. ta-VNS will be administered for 10 minutes before gaming and in-lab target behavior training. A typical BFT session will consist of one hour of gaming, training on healthy lifestyle behaviors (i.e., healthy sleep, nutrition, and relaxation habits), as well as procedures designed to promote transfer of behavior changes to daily life. Ta-VNS will be administered for 10 minutes before gaming and in-lab target behavior training. Training sessions in both conditions will be scheduled based on participants' availability, with the options for sessions scheduled to be as close as every weekday over 2 weeks or as loosely as every other weekday (i.e., over a 4-week span). If a caregiver is available, they will receive training on how to best support participants in their therapeutic program. After the training ends, both groups will receive 4 follow-up phone calls approximately one week apart to promote integration of the gained skills into everyday life. Outcomes measured will include cognitive processing speed, cognitive function on laboratory tests, and spontaneous performance of everyday activities with important cognitive components in daily life.",[153,328,329,330,331,332,333,334],"ME\u002FCFS Following EBV-associated Infectious Mononucleosis","ME\u002FCFS Following COVID-19","Chronic Fatigue","Chronic Fatigue Syndrome (CFS)","Brain Fog","Cognitive Impairment","Cognitive Dysfunction",[153,330,336,333,334,337,338,339],"Brain fog","post-viral syndrome","Cognitive Rehabilitation","CICT","2026-08-12",{"date":342,"type":35},"2026-08-14",{"date":344,"type":35},"2026-06-23",{"date":346,"type":23},"2028-06",{"name":41,"class":42},{"id":349,"slug":350,"hasResults":12,"nctId":351,"briefTitle":352,"officialTitle":352,"acronym":353,"eligibilityCriteria":354,"healthyVolunteers":18,"sex":187,"minAge":20,"maxAge":4,"enrollmentInfo":355,"targetDuration":4,"studyType":24,"phases":357,"briefSummary":358,"conditions":359,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":340,"lastUpdatePostDateStruct":362,"startDateStruct":363,"completionDateStruct":365,"leadSponsor":367,"locationsCount":43},"100568315","a-telehealth-intervention-to-increase-patient-preparedness-for-surgery-in-latinas-100568315","NCT06679621","A Telehealth Intervention to Increase Patient Preparedness for Surgery in Latinas","TIPPS-Urogyn","Inclusion Criteria:\n\nPatients who\n\n* Self-report as female\n* 18 years and older\n* Self-report as Hispanic ethnicity\n* Scheduled to undergo a surgery for a urogynecologic condition in the operating room (surgery to correct pelvic organ prolapse, urinary\u002Ffecal incontinence, fistula, urethral masses)\n* Able to read and write English and\u002For Spanish\n\nUrogynecologists who -Routinely perform urogynecologist surgeries to correct pelvic organ prolapse, urinary\u002Ffecal incontinence, fistula, urethral masses\n\nNurses who\n\n* Spend most of their time at a urogynecologic clinic\n* Engage in the process of preparing patients for urogynecologic surgery\n\nExclusion Criteria:\n\nPatients who\n\n* Self-report as male\n* Are less than 18 years of age\n* Self-report as not of Hispanic ethnicity\n* Scheduled to undergo a surgery for a condition that is not urogynecologic or is not in the operating room\n* Patients undergoing procedures that are traditionally performed in the office (bladder Botox, pelvic floor Botox, urethral bulking)\n\nUrogynecologists who\n\n-Do not routinely perform urogynecologic surgery\n\nNurses who\n\n* Do not spend most of their time at a urogynecology clinic\n* Do not engage in the process of preparing patients for urogynecologic surgery",{"count":356,"type":23},357,[55],"There are 3 aims of this study. In Aim 1 community patient partners will be enrolled to help guide the research being performed in all of the aims. Investigators will also administer a survey that will help determine factors associated with surgical preparedness. In Aim 2 investigators will develop an intervention to increase surgical preparedness using Human Centered Design Methods. Aim 3 will pilot test the intervention using mixed methods to determine feasibility and implementation outcomes.",[360,361],"Incontinence","Prolapse",{"date":342,"type":35},{"date":364,"type":35},"2024-11-01",{"date":366,"type":23},"2027-06-01",{"name":41,"class":42},{"id":369,"slug":370,"hasResults":12,"nctId":371,"briefTitle":372,"officialTitle":373,"acronym":4,"eligibilityCriteria":374,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":375,"targetDuration":4,"studyType":24,"phases":377,"briefSummary":378,"conditions":379,"keywords":381,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":387,"lastUpdatePostDateStruct":388,"startDateStruct":389,"completionDateStruct":391,"leadSponsor":393,"locationsCount":279},"100602820","remote-intervention-to-prevent-overdose-100602820","NCT07128485","Remote Intervention to Prevent Overdose","A Remote Intervention to Prevent Overdose Among People Who Use Stimulants and\u002For Opioids","Inclusion Criteria:\n\n* 18 years old\n* English-speaking and reading\n* Report using illicit opioids and\u002For stimulants (including counterfeit pills) within the past 3 months per the ASSIST\n* Able and willing to provide informed consent\n* Be able and willing to provide the names and contact information of three close contacts to reach if the participant cannot be reached\n\nExclusion Criteria:\n\n* Living in a restricted environment (e.g., prison)",{"count":376,"type":23},100,[55],"This Type 1 hybrid effectiveness-implementation randomized controlled trial, A Remote Intervention to Prevent Overdose among People who Use Stimulants and\u002For Opioids, aims to address the United States opioid crisis driven by fentanyl and other synthetic opioids by reducing overdose rates. It is supported by and included in the HEAL Initiative. This study would be the first national, fully remote trial to assess the impact of remote education on overdose outcomes, using a novel 2x2 design crossing remote education with remote access support. This research will inform scalability around remote education programs to address the nation's opioid overdose crisis.",[380],"Accidental Overdose of Opiate",[382,383,384,385,386],"overdose prevention","fentanyl","opioid use disorder","stimulant use disorder","accidental overdose","2026-08-10",{"date":340,"type":35},{"date":390,"type":23},"2027-01",{"date":392,"type":23},"2027-11",{"name":41,"class":42},{"id":395,"slug":396,"hasResults":12,"nctId":397,"briefTitle":398,"officialTitle":399,"acronym":4,"eligibilityCriteria":400,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":401,"targetDuration":4,"studyType":24,"phases":402,"briefSummary":403,"conditions":404,"keywords":407,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":387,"lastUpdatePostDateStruct":410,"startDateStruct":411,"completionDateStruct":413,"leadSponsor":415,"locationsCount":43},"100538726","evaluation-of-free-gingival-graft-timing-100538726","NCT06294587","Evaluation of Free Gingival Graft Timing","Evaluation of Free Gingival Graft Timing in Staged Guided Bone Regeneration: A Randomized Controlled Trial","Inclusion Criteria:\n\n* • At least 18 years old\n\n  * No uncontrolled medical conditions or medications that will affect their bone healing.\n  * Good oral hygiene is defined as a full-mouth plaque score ≤25%11.\n  * Must be able to read and understand the informed consent document.\n  * Has a need for implants to replace missing tooth\u002Fteeth in at least 1 quadrant of the mouth.\n  * Insufficient alveolar ridge width for endosseous implant placement, defined as 5 mm or less, as determined by bone sounding and CBCT scan.\n  * The patient and\u002For guardian is willing and able to comply with pre-operative and post-operative diagnostic and clinical evaluations required.\n  * The patient is not pregnant or breastfeeding.\n\nExclusion Criteria:\n\n* Active infectious diseases.\n\n  * Liver or kidney dysfunction\u002Ffailure.\n  * Uncontrolled diabetes (HbA1c ≥ 8.5).\n  * Active cancer treatment - such as active chemotherapy radiation therapy, or radiotherapy performed within ≤12 months from the procedure.\n  * Taking medications that will affect their bone healing (for example, bisphosphonates and long-term anti-inflammatory medications).\n  * Metabolic bone diseases that affect bone healing such as osteoporosis.\n  * Pregnant or lactating women (self-reported).\n  * Current tobacco and Marijuana smokers have 10 or more cigarettes per day, and former smokers (\\> 10 cigarettes) who quit \\< 10 ago (self-reported).\n  * Poor oral hygiene.\n  * Vertical loss of bone at the edentulous ridge.\n  * History of periodontal disease.\n  * The patient is pregnant or breastfeeding",{"count":324,"type":23},[55],"This clinical trial aims to compare and evaluate the clinical outcomes between two distinct treatment sequences: free gingival graft surgery preceding guided bone regeneration and guided bone regeneration followed by free gingival graft.",[405,406],"Ridge Augmentation","Alveolar Mucosa",[405,408,409],"Attached mucosa","Dental implants",{"date":340,"type":35},{"date":412,"type":35},"2024-08-12",{"date":414,"type":23},"2028-08-30",{"name":41,"class":42},{"id":417,"slug":418,"hasResults":12,"nctId":419,"briefTitle":420,"officialTitle":420,"acronym":4,"eligibilityCriteria":421,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":422,"enrollmentInfo":423,"targetDuration":4,"studyType":24,"phases":425,"briefSummary":426,"conditions":427,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":387,"lastUpdatePostDateStruct":429,"startDateStruct":430,"completionDateStruct":432,"leadSponsor":433,"locationsCount":43},"100538342","early-phase-1-longitudinal-tspo-pet-imaging-with-18fdpa-714-in-ppmi-ppmi-dpa-714-pet-imaging-100538342","NCT06289582","Longitudinal TSPO PET Imaging With [18F]DPA-714 in PPMI (PPMI DPA-714 PET Imaging)","Inclusion Criteria:\n\n* A prodromal PD and Healthy participant enrolled in PPMI Clinical protocol\n* A PD participant enrolled in PPMI Clinical protocol who has not started symptomatic treatment at time of enrollment or in the first 2 years of participation.\n* Able to provide informed consent\n* Must have screening genetic testing documenting high binder at the at the known TSPO gene polymorphism (rs6971)\n* Male or Female (Females must meet additional criteria specified below, as applicable)\n\n  • Females must be of non-childbearing potential or using a highly effective method of birth control 14 days prior to until at least 24 hours after injection of \\[18F\\]DPA-714\n* Non-childbearing potential is defined as a female that must be either postmenopausal (no menses for at least 12 months prior to PET scan) or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy).\n* Highly effective method of birth control is defined as practicing at least one of the following: A birth control method that results in a less than 1% per year failure rate when used consistently and correctly, such as oral contraceptives for at least 3 months prior to injection, an intrauterine device (IUD) for at least 2 months prior to injection, or barrier methods, e.g., diaphragm or combination condom and spermicide. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) is not acceptable.\n\n  * Females of childbearing potential must not be pregnant, breastfeeding or lactating.\n  * Includes a negative urine pregnancy test prior to injection of \\[18F\\]DPA-714 on day of PET scan.\n\nExclusion Criteria:\n\n* Exposure to a total effective dose equivalent of 50 millisievert (mSv) for the whole body, which is the annual limit established by the US Code of Federal Regulations , during the past year.\n* Any other medical or psychiatric condition or lab abnormality, which in the opinion of the Site Investigator might preclude participation.","99 Years",{"count":424,"type":23},60,[168],"The overall goal of this protocol is to investigate \\[18F\\]DPA-714 binding in prodromal and early manifest Parkinson's Disease (PD) and to determine the baseline and change from baseline in \\[18F\\]DPA-714 binding in PD participants during a 24-month interval.\n\nPrimary Objectives\n\n* To compare \\[18F\\]DPA-714 binding in prodromal and manifest PD and healthy volunteers.\n* To determine the longitudinal change in \\[18F\\]DPA-714 during a 24-month interval for prodromal and early initially untreated PD participants.\n\nSecondary Objectives\n\n* To evaluate the correlation between baseline \\[18F\\]DPA-714 and PPMI clinical and biomarker outcomes.\n* To evaluate the correlation between the longitudinal change of \\[18F\\]DPA-714 and PPMI clinical and biomarker outcomes\n* To acquire safety data following injection of \\[18F\\]DPA-714",[428],"Parkinson Disease",{"date":340,"type":35},{"date":431,"type":35},"2024-08-14",{"date":346,"type":23},{"name":41,"class":42},{"id":435,"slug":436,"hasResults":12,"nctId":437,"briefTitle":438,"officialTitle":439,"acronym":440,"eligibilityCriteria":441,"healthyVolunteers":12,"sex":19,"minAge":442,"maxAge":287,"enrollmentInfo":443,"targetDuration":4,"studyType":24,"phases":445,"briefSummary":446,"conditions":447,"keywords":449,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":387,"lastUpdatePostDateStruct":454,"startDateStruct":455,"completionDateStruct":457,"leadSponsor":459,"locationsCount":43},"100499640","diet-interventions-remitted-and-evaluated-as-complementary-treatments-for-pain-100499640","NCT05785884","Diet Interventions: Remitted and Evaluated as Complementary Treatments for Pain","Diet Interventions: Remitted and Evaluated as Complementary Treatments for Pain (DIRECTPain)","DIRECTPain","Inclusion Criteria:\n\n1. diagnosis of knee OA\n2. pain in at least 4\u002F7 days\u002Fweek for the past 3 months (pain of ≥3\u002F10 on 0-10 scale)\n3. age between 40-75\n4. average daily consumption of \\>100 g carbohydrates (based on Phase 1 food checklist)\n5. understanding of verbal and written English\n6. self-identification as either NHB or NHW\n7. BMI between 25 and 40 kg\u002Fm2\n\nExclusion Criteria:\n\n1. unmedicated diabetes\n2. unwillingness to follow prescribed diets\n3. recent weight change (\\>4 kg in past month)\n4. currently on a diet\n5. history of eating disorders or other psychiatric disorders requiring hospitalization within the past 6 months\n6. digestive diseases\n7. difficulty chewing or swallowing\n8. reliance on others for meal preparation\n9. cardiovascular or pulmonary disease\n10. daily opioid pain medications\n11. use of medications known to alter metabolism or digestion (e.g., proton-pump inhibitors)\n12. use of anti-hypertensive medications that affect glucose tolerance\n13. use of tobacco\n14. participation in extreme exercise\n15. knee replacement","40 Years",{"count":444,"type":23},200,[55],"Knee osteoarthritis (OA) is the most prevalent form of arthritis, a significant cause of disability in the U.S. With an aging population and the rise in obesity rates, the prevalence of knee OA is expected to climb, significantly reducing quality of life (QOL) for those suffering from this debilitating condition. Current national efforts to reduce analgesic utilization highlight the critical need for safe, effective, and accessible alternatives for pain relief. Low-carbohydrate diets (LCDs) reduce inflammation and pain independent of weight loss, indicating that diet interventions offer a non-pharmacological complementary treatment. However, differences exist in metabolism that are rarely addressed in diet intervention studies. Thus, it is important to assess the potential of different diets in a broad population of chronic pain sufferers to determine the potential of diets to reduce knee OA pain. We have shown that a LCD was associated with reduced evoked knee OA pain, daily pain and oxidative stress when compared to either a USDA diet or a diet-as-usual control. Both experimental diets reduced weight to a similar degree, arguing that diet quality was likely the key factor in pain reduction, as opposed to weight loss. However, previous studies comparing diets have utilized diet prescriptions with less control for adherence to the diets. To overcome this obstacle, and in line with our recent work, we will provide all snacks and meals during the diet intervention to increase adherence and retention in the study, allowing for better control over diet interventions and consistency of foods within each study group. We will recruit adults with knee OA (N=200) to complete our two-phase protocol. Phase 1 will involve a 1-week diet run-up that will allow for quantification of pain measures, psychosocial variables (socioeconomic status, nutritional knowledge, proximity to grocery stores, food insecurity), and diet quality to provide a baseline for comparison. Phase 2 will be a 6-week randomized diet intervention (LCD or USDA diet) in which both groups will be provided with all meals at the direction of study personnel and input from participants. Evoked pain tasks, measures of pain disability, severity, catastrophizing, and interference will be assessed every 3 weeks in addition to QOL measures, mood, and depression. Physiological variables will be assessed through blood draws (inflammatory profile) and dual-energy X-ray absorptiometry scans (DXA; body composition, visceral fat) at the end of Phases 1 and 2. This will be the first study to examine the efficacy of these diets to reduce knee OA pain with an emphasis on interactions with biopsychosocial variables. Changes in all pain measures following Phase 2 will be assessed with respect to published measures of clinically-meaningful differences in pain and disability, as well as for statistical significance. The central hypothesis is that the LCD will improve pain and QOL in participants with knee OA more than the USDA diet, but that both will be beneficial.\n\nSpecific Aim 1: To investigate the efficacy of the diets to reduce pain and improve QOL.\n\nHypothesis 1: The LCD group will show significantly greater reductions in: a) self-reported pain (\\>1.7 in pain intensity) and, b) evoked pain (\\>30%) when compared to the USDA diet.\n\nHypothesis 2: The LCD group will show greater improvements in: a) QOL, b) mood, and c) self-reported improvement (\\>50% participants reporting \"much improved\" or \"very much improved\").\n\nHypothesis 3 (secondary): Both diets will result in improved pain disability, severity, catastrophizing and pain related fear; the LCD will outperform the USDA diet.\n\nSpecific Aim 2: To explore individual differences in diet and baseline measures.\n\nHypothesis 1: Baseline diet quality will be negatively associated with baseline pain sensitivity Hypothesis 2: Those reporting greater a) food insecurity and\u002F or b) proximity to grocery stores will report poorer-quality diets.\n\nSpecific Aim 3: To determine whether physiological variables contribute to diet effects or lack thereof. Hypothesis 1: Baseline physiological measures (inflammatory profile) will predict: a) pain sensitivity, and b) reductions in pain.\n\nHypothesis 2: Change in physiological measures (inflammatory profile, adiposity, leptin) will be related to: a) change in pain measures, b) change in QOL, c) self-reported improvement and, d) mood.",[448],"Knee Osteoarthritis",[450,451,452,453],"diet","chronic pain","knee osteoarthritis","racial differences",{"date":340,"type":35},{"date":456,"type":35},"2023-02-01",{"date":458,"type":23},"2027-06-30",{"name":41,"class":42},{"id":461,"slug":462,"hasResults":12,"nctId":463,"briefTitle":464,"officialTitle":465,"acronym":4,"eligibilityCriteria":466,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":144,"enrollmentInfo":467,"targetDuration":4,"studyType":24,"phases":468,"briefSummary":469,"conditions":470,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":387,"lastUpdatePostDateStruct":472,"startDateStruct":473,"completionDateStruct":475,"leadSponsor":477,"locationsCount":43},"100489667","early-phase-1-positron-emission-tomography-pet-imaging-of-neuroinflammation-in-patients-with-neurological-dysfunction-after-severe-acute-respiratory-syndrome-coronavirus-2-sars-cov-2-infection-100489667","NCT05656105","Positron Emission Tomography (PET) Imaging of Neuroinflammation in Patients With Neurological Dysfunction After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2) Infection","PET Imaging of Neuroinflammation in Patients With Neurological Dysfunction After SARS-CoV-2 Infection","Inclusion Criteria:\n\n1. 18 to 65 years of age\n2. Healthy volunteer OR Clinical diagnosis of post-acute sequelae of SARS-CoV-2 (PASC)\n3. High or mixed affinity binder for TSPO ligands based on genotyping for single nucleotide polymorphism (SNP) rs6971.\n4. PASC participants must have been previously infected with SARS-CoV-2. Their neurological symptoms must have been present for at least four weeks prior to the enrollment.\n5. Healthy control participants must have no neurological symptoms\n\nExclusion Criteria:\n\n1. Contraindication to MRI\n2. Pregnancy\n3. Lactation\n4. Individuals who are unable to participate in the imaging portion due to severity of their medical condition\n5. Chronic infectious disease (e.g. HIV, HCV)\n6. Viral or bacterial illness requiring medical attention and\u002For antibiotics within 1 month of study participation\n7. Diagnosis of cancer, including leukemia\n8. Blood or blood clotting disorder\n9. Except for individuals with Multiple Sclerosis (MS), a diagnosis of autoimmune disease is exclusionary\n10. Positive urine β-hCG test day of procedure or a serum human chorionic gonadotropin (hCG) test within 48 hours prior to the administration of \\[18F\\]DPA-714.11.\n\n11Currently enrolled in a clinical trial utilizing experimental therapies. 12. Currently taking experimental therapies 13. Low affinity binder for TSPO ligands based on genotyping for SNP rs6971.\n\nThe following exclusionary criteria apply only to PASC patients and healthy controls:\n\n14\\. Self-reported history of moderate or severe traumatic brain injury 15. Self-reported history of whiplash injury 16. Self-reported history of Inflammatory bowel disease (IBD). (Individuals with Irritable Bowel Syndrome (IBS) and no signs of inflammation will be allowed to participate.) 17. The following blood test results (at screening) will be exclusionary: 18. Rheumatoid Factor (RF) =\\> 14 IntUnits\u002FmL, 19. Anti-nuclear antibody (ANA) \\> 1:80, 20. Erythrocyte sedimentation rate (ESR) \\> 60mm\u002Fhour, 21.High sensitivity C-reactive protein (hsCRP) \\> 10mg\u002FL, 22. Complete blood count (CBC) results indicating acute infection, anemia, or other condition, 23. T3, T4, or thyroid-stimulating hormone (TSH) levels out of normal range, 24. Fasting glucose \\> 100 mg\u002FdL, 25. Blood chemistry results indicating organ damage or other serious medical condition 26. Use of illicit substances within the past 6 months 27. Self-reported diagnosis of Type I or Type II diabetes 28. Healthy controls must not regularly take over-the-counter anti-inflammatory medication, analgesics (except aspirin), or sleep medication",{"count":424,"type":23},[168],"This clinical imaging study will use the small molecule translocator protein (TSPO) ligand, Fluorodeoxyglucose(18F)-labeled DPA-714, to visualize and quantify neuroinflammation in individuals with post-acute sequelae of SARS-CoV-2 (PASC) . The brain uptake of DPA-714 will be contrasted with healthy subjects.",[471],"SARS CoV-2 Post-Acute Sequelae",{"date":340,"type":35},{"date":474,"type":35},"2023-11-10",{"date":476,"type":23},"2028-06-01",{"name":41,"class":42},{"id":479,"slug":480,"hasResults":12,"nctId":481,"briefTitle":482,"officialTitle":482,"acronym":4,"eligibilityCriteria":483,"healthyVolunteers":12,"sex":19,"minAge":442,"maxAge":484,"enrollmentInfo":485,"targetDuration":4,"studyType":24,"phases":487,"briefSummary":488,"conditions":489,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":387,"lastUpdatePostDateStruct":491,"startDateStruct":492,"completionDateStruct":494,"leadSponsor":495,"locationsCount":43},"100390340","phase-1-molecular-imaging-probes-to-inform-heterogeneity-in-idiopathic-pulmonary-fibrosis-100390340","NCT04362644","Molecular Imaging Probes to Inform Heterogeneity in Idiopathic Pulmonary Fibrosis","Inclusion Criteria:\n\n1. Age between 40-85 years old.\n2. A diagnosis of IPF that fulfills American Thoracic Society (ATS) \u002F European Respiratory Society (ERS) 2018 consensus criteria within 5 years.\n3. Ability and willingness to give informed consent and adhere to study requirements.\n4. Ratio of forced expiratory volume in 1 second to forced vital capacity (FEV1\u002FFVC) \\>0.70.\n5. High or mixed affinity binder for TSPO ligands based on genotyping for single-nucleotide polymorphism (SNP)rs6971.\n\nExclusion Criteria:\n\n1. Acute exacerbation of IPF within \\\u003C30 days\n2. Diagnosis of Diabetes Mellitus (Type 1 or Type 2).\n3. Diagnoses of current infection by clinical or microbial assessments.\n4. Treatment for \\>14 days within the preceding month with \\>20 mg. prednisone (or equivalent) or any treatment during the last month with a cellular immunosuppressant.\n5. Subjects with prior radiation therapy to the thorax.\n6. Women who are pregnant, or who are breastfeeding. IPF is a disease of older adults, and male predominant, so this will not be a frequent consideration.\n7. Severe cardiovascular disease, defined as any of the following within the preceding 12 weeks: acute myocardial infarction or unstable angina, a coronary revascularization procedure, or stroke.\n8. Subjects with known liver disease.\n9. Diagnosis of any active cancer with the exception of basal cell carcinoma of skin.\n10. Low affinity binder for TSPO ligands based on genotyping for SNP rs6971.\n11. Active cigarette smoking or vaping","85 Years",{"count":486,"type":23},10,[78],"The purpose of the study is to see if imaging with fluorine-18 Fluorodeoxyglucose (\\[18F\\] FDG) and fluorine-18 Displacement Per Atom (\\[18F\\]DPA-714) using positron emission tomography and computed tomography (PET\u002FCT) will show lung inflammation and fibrosis in patients diagnosed with idiopathic pulmonary fibrosis (IPF). This study may help physicians and researchers better understand how best to treat patients with IPF in the future.",[490],"Idiopathic Pulmonary Fibrosis",{"date":340,"type":35},{"date":493,"type":35},"2020-12-08",{"date":296,"type":23},{"name":41,"class":42},{"id":497,"slug":498,"hasResults":12,"nctId":499,"briefTitle":500,"officialTitle":500,"acronym":501,"eligibilityCriteria":502,"healthyVolunteers":18,"sex":19,"minAge":503,"maxAge":4,"enrollmentInfo":504,"targetDuration":4,"studyType":24,"phases":506,"briefSummary":507,"conditions":508,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":387,"lastUpdatePostDateStruct":510,"startDateStruct":511,"completionDateStruct":513,"leadSponsor":515,"locationsCount":43},"100347867","phase-1-uab-alzheimers-disease-center-core-cohort---tau-imaging-substudy-100347867","NCT03809351","UAB Alzheimer's Disease Center Core Cohort - Tau Imaging Substudy","AV1451 ADC","Inclusion Criteria:\n\n1. Enrollment in the UAB-ADC study under a separate IRB-approved research protocol.\n2. Enrollment in the UAB-ADC amyloid-PET substudy under a separate IRB-approved research protocol. The amyloid-PET study does not have to have been completed prior to enrollment and participation in this tau-PET study.\n3. Negative urine or serum hCG test within 2 days of \\[F-18\\]AV-1451 administration in women of child bearing potential. Women who are post-menopausal with at least 1 year since last menses or documented surgical sterilization will not require pregnancy testing.\n\nExclusion Criteria:\n\n1. Meets any exclusion criteria for the UAB-ADC study.\n2. Inability or contraindication for undergoing MRI and\u002For PET imaging\n3. Inability to participate in the imaging studies due to severity of dementia","50 Years",{"count":505,"type":23},160,[78],"The primary objective of this study is to measure the concentration and the regional brain distribution of pathologic tau deposition using the PET tracer AV-1451 in participants in the UAB-ADC cohort. The amount and distribution of AV-1451 in the brain will be correlated to demographic, clinical, genetic, and biospecimen data acquired through the separate ongoing UAB-ADC study. Assessment of interactions between race and vascular risk factors, brain tau levels measured with AV-1451-PET, and cognitive status will be the primary outcome of this imaging study. Individuals participating in this AV-1451-PET\u002FMRI study will also be enrolled in an ongoing \\[C-11\\]PiB-PET\u002FMRI study (IRB-300001005, IND-138128), and their amyloid, tau and cognitive statuses will be compared in terms of race and vascular risk factors.",[509],"Alzheimer Disease",{"date":340,"type":35},{"date":512,"type":35},"2020-07-08",{"date":514,"type":23},"2028-07",{"name":41,"class":42},{"id":517,"slug":518,"hasResults":12,"nctId":519,"briefTitle":520,"officialTitle":520,"acronym":521,"eligibilityCriteria":522,"healthyVolunteers":18,"sex":19,"minAge":503,"maxAge":4,"enrollmentInfo":523,"targetDuration":4,"studyType":24,"phases":524,"briefSummary":525,"conditions":526,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":387,"lastUpdatePostDateStruct":527,"startDateStruct":528,"completionDateStruct":530,"leadSponsor":532,"locationsCount":43},"100324386","phase-2-uab-alzheimers-disease-center-core-cohort---imaging-substudy-100324386","NCT03503331","UAB Alzheimer's Disease Center Core Cohort - Imaging Substudy","PiB ADC","Inclusion Criteria:\n\n\\- 1. Enrollment in the UAB-ADC study under a separate IRB-approved research protocol (IRB-300000169).\n\n2\\. Negative urine or serum B-hCG test within 2 days of \\[C-11\\]PiB administration in women of child bearing potential. Women who are post-menopausal with at least 1 year since last menses or documented surgical sterilization will not require pregnancy testing.\n\nExclusion Criteria:\n\n1. Meets any exclusion criteria for the UAB-ADC study (IRB-300000169).\n2. Inability or contraindication for undergoing MRI and\u002For PET imaging\n3. Inability to participate in the imaging studies due to severity of dementia",{"count":505,"type":23},[148],"The primary objective of this study is to measure the concentration and the regional brain distribution of pathologic amyloid deposition using the PET tracer \\[C-11\\]PiB in participants in the UAB Alzheimer's Disease Center cohort. Assessment of interactions between race and vascular risk factors, brain amyloid levels measured with \\[C-11\\]PiB-PET, and cognitive status will be the primary outcome of this imaging study.",[509],{"date":340,"type":35},{"date":529,"type":35},"2018-04-20",{"date":531,"type":23},"2028-10",{"name":41,"class":42},{"id":534,"slug":535,"hasResults":12,"nctId":536,"briefTitle":537,"officialTitle":538,"acronym":4,"eligibilityCriteria":539,"healthyVolunteers":18,"sex":19,"minAge":540,"maxAge":4,"enrollmentInfo":541,"targetDuration":4,"studyType":24,"phases":543,"briefSummary":544,"conditions":545,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":387,"lastUpdatePostDateStruct":546,"startDateStruct":547,"completionDateStruct":549,"leadSponsor":550,"locationsCount":43},"100320873","phase-1-the-university-of-alabama-at-birmingham-uab-neuroinflammation-in-parkinsons-disease-tspo--positron-emission-tomography-pet-substudy-100320873","NCT03457493","The University of Alabama at Birmingham (UAB) Neuroinflammation in Parkinson's Disease-TSPO- Positron Emission Tomography (PET) Substudy","UAB Neuroinflammation in Parkinson's Disease - TSPO-PET Substudy","Inclusion Criteria for all cohorts:\n\n1. Enrollment in either the UAB Innate and Adaptive Immunity in Parkinson Disease (Clinical Research Core) study or UAB Longitudinal \\[18F\\]DPA-714 Imaging in a Parkinson Disease Cohort study under the separate UAB-approved research protocols (IRB-300001745 and IRB-300011684 respectively, PI Yacoubian)\n2. Negative urine or serum Human chorionic gonadotropin (hCG) test within 2 days of \\[18F\\]DPA-714-PET administration in women of childbearing potential. Women who are post-menopausal with at least 1 year since last menses or documented surgical sterilization will not require pregnancy testing.\n3. High or mixed affinity binder for TSPO ligands based on genotyping for single nucleotide polymorphism (SNP) rs6971.\n\nExclusion Criteria for all cohorts:\n\n1. Meets any exclusion criteria for the UAB Innate and Adaptive Immunity in Parkinson's Disease (Clinical Research Core) study or UAB Longitudinal \\[18F\\]DPA-714 Imaging in a Parkinson's Disease Cohort study.\n2. Contraindication to MRI and\u002For PET imaging\n3. Inability to participate in the imaging studies due to severity of PD or other medical comorbidities.\n4. Low-affinity binder for TSPO ligands based on genotyping for SNP rs6971.\n\nInclusion Criteria specific for UDALL 5-year Follow-up Cohort\n\n1\\. Parkinson's Disease participant enrolled in UDALL Baseline Cohort. Baseline imaging to be completed no more than 6 years prior.\n\nInclusion of Women and Minorities\n\nParticipants 30 years of age or older will be eligible for study participation. No other discriminatory factors, including age, sex, or ethnic background will be used to determine eligibility. Every effort will be made to ensure that minorities are recruited for study participation.","30 Years",{"count":542,"type":23},205,[78,148],"The primary objective of this substudy is to measure the concentration and the regional brain distribution of activated brain microglia\u002Fmacrophages using the PET ligand \\[18F\\]DPA-714 in participants enrolled in the UAB Innate and Adaptive Immunity in Parkinson's Disease (Clinical Research Core) and Longitudinal \\[18F\\]DPA-714 Imaging in a Parkinson Disease Cohort studies. The PET tracer \\[18F\\]DPA-714 binds to the 18 kDa translocator protein (TSPO, also known as the peripheral benzodiazepine receptor) in the mitochondria of activated microglia\u002Fmacrophages and provides a non-invasive measure of neuroinflammation. The amount and distribution of \\[18F\\]DPA-714 in the brain will be correlated to clinical data acquired through the separate ongoing UAB Innate and Adaptive Immunity in Parkinson Disease (Clinical Research Core) and Longitudinal \\[18F\\]DPA-714 Imaging in a Parkinson Disease Cohort studies. The primary objective of this study is to determine if patients with PD have higher levels of neuroinflammation than healthy controls as measured with \\[18F\\]DPA-714-PET\u002FMRI.",[428],{"date":340,"type":35},{"date":548,"type":35},"2018-03-22",{"date":346,"type":23},{"name":41,"class":42},{"id":552,"slug":553,"hasResults":12,"nctId":554,"briefTitle":555,"officialTitle":556,"acronym":4,"eligibilityCriteria":557,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":558,"targetDuration":4,"studyType":24,"phases":560,"briefSummary":561,"conditions":562,"keywords":564,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":569,"lastUpdatePostDateStruct":570,"startDateStruct":571,"completionDateStruct":573,"leadSponsor":574,"locationsCount":43},"100651493","assessing-the-feasibility-of-the-heart-care-pairs-intervention-100651493","NCT07760350","Assessing the Feasibility of the \"Heart Care Pairs\" Intervention","A Mixed Methods Pilot Feasibility Study of a Primary Care-based Dyadic Cardiovascular Risk Reduction Intervention: \"Heart Care Pairs\"","Inclusion Criteria:\n\n* Diagnosed with hypertension and\u002For taking blood pressure lowering medications\n* willing to invite a supportive partner to participate for the duration of the study including an enrollment and baseline measurement visit, up to 6 intervention visits, and a post-intervention measurement visit.\n\nExclusion Criteria:\n\n* untreated serious mental illness or cognitive decline that would limit ability to provide informed consent",{"count":559,"type":23},85,[55],"The researchers will invite 30 patients in primary care who have high blood pressure to participate in this health program with a supportive partner of their choosing (these will be the \"participant pairs\"). Participant pairs will be invited to complete the Heart Care Pairs health program that will include up to six sessions each including 1) some education on a health habit like physical activity and heart healthy foods, 2) goal setting together, and 3) talk about healthy communication to support one another with heart healthy habits. The researchers will work with participants to address things that get in the way of coming for visits like offering transportation and offering telehealth visits. The researchers are seeing how this program works in real life so participants will be asked to complete as many sessions as they want to and can attend. The researchers will be interested in what participants think about the sessions, if they were satisfied with the visits, and if they would recommend the program to others in their community. The researchers will ask these questions in interviews with participants. The researchers will also ask up to 25 primary care workers about how they view the program as helpful to their work with patients with high blood pressure and whether they would refer more patients to the program in the future.",[563],"Hypertension (HTN)",[565,566,567,568],"hypertension","primary care","integrated behavioral health","dyadic intervention","2026-08-07",{"date":340,"type":35},{"date":572,"type":23},"2026-11-01",{"date":458,"type":23},{"name":41,"class":42},""]